Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
Toronto, Ontario–(Newsfile Corp. – September 12, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…
The $2 Trillion Valuation Debate Skips What Anthropic Knows
Pharmacore secures funding to improve medication regimen reviews in long-term care